InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
64,032.51
(
1.82%
)
Post# of 111
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

e-ore

Send PM Follow Ignore
Followers 281
Posts 25967
Boards Moderated 6
Alias Born 01/27/2009

e-ore

Member Level

Re: None

Monday, 01/11/2016 11:45:50 PM

Monday, January 11, 2016 11:45:50 PM

Post# of 111
"Our intention to initiate clinical trials with our lead anti-cancer drug (AGX51-E2) is now supported by a commitment from The Trout Group, a highly respected investment firm in NYC. A contractual arrangement was completed in the latter part of 2014 and efforts are currently underway to present our technology and plans to potential investors. The Trout Group is taking an active part in these efforts and we expect that we will raise sufficient funds to launch preclinical efforts to achieve FDA approval for an IND that will allow us to initiate the first clinical trial in mid-2016."

http://www.troutgroup.com/about-us/our-company

http://www.troutgroup.com/clients/overview

My posts are my opinion. Do not be influenced by anything you read on any message board website unless you can confirm it.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up